Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H20F4N8O2 |
| Molecular Weight | 528.4616 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CC1=NC=CN1C2=CC(F)=C(NC(=O)C3=CC(=NN3C4=CC5=C(ON=C5N)C=C4)C(F)(F)F)C=C2
InChI
InChIKey=OFJRNBWSFXEHSA-UHFFFAOYSA-N
InChI=1S/C24H20F4N8O2/c1-34(2)12-21-30-7-8-35(21)13-3-5-17(16(25)10-13)31-23(37)18-11-20(24(26,27)28)32-36(18)14-4-6-19-15(9-14)22(29)33-38-19/h3-11H,12H2,1-2H3,(H2,29,33)(H,31,37)
| Molecular Formula | C24H20F4N8O2 |
| Molecular Weight | 528.4616 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Razaxaban (also known as BMS-561389 or DPC 906) is an oral factor Xa inhibitor that was being developed for the treatment of thrombosis. It showed excellent results in the lab for efficacy and bioavailability and was therefore selected for further development. In a phase 1 clinical trial with healthy subjects, Razaxaban was well tolerated with minor bleeding. However, higher bleeding was reported in thrombosis patients in a phase 2 clinical trial, and the development of this drug was therefore discontinued in 2005.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:42:36 GMT 2025
by
admin
on
Mon Mar 31 18:42:36 GMT 2025
|
| Record UNII |
3K2509846L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C263
Created by
admin on Mon Mar 31 18:42:36 GMT 2025 , Edited by admin on Mon Mar 31 18:42:36 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8445
Created by
admin on Mon Mar 31 18:42:36 GMT 2025 , Edited by admin on Mon Mar 31 18:42:36 GMT 2025
|
PRIMARY | |||
|
300000036988
Created by
admin on Mon Mar 31 18:42:36 GMT 2025 , Edited by admin on Mon Mar 31 18:42:36 GMT 2025
|
PRIMARY | |||
|
DTXSID40870249
Created by
admin on Mon Mar 31 18:42:36 GMT 2025 , Edited by admin on Mon Mar 31 18:42:36 GMT 2025
|
PRIMARY | |||
|
3K2509846L
Created by
admin on Mon Mar 31 18:42:36 GMT 2025 , Edited by admin on Mon Mar 31 18:42:36 GMT 2025
|
PRIMARY | |||
|
C84134
Created by
admin on Mon Mar 31 18:42:36 GMT 2025 , Edited by admin on Mon Mar 31 18:42:36 GMT 2025
|
PRIMARY | |||
|
C500057
Created by
admin on Mon Mar 31 18:42:36 GMT 2025 , Edited by admin on Mon Mar 31 18:42:36 GMT 2025
|
PRIMARY | |||
|
204102
Created by
admin on Mon Mar 31 18:42:36 GMT 2025 , Edited by admin on Mon Mar 31 18:42:36 GMT 2025
|
PRIMARY | |||
|
CHEMBL206335
Created by
admin on Mon Mar 31 18:42:36 GMT 2025 , Edited by admin on Mon Mar 31 18:42:36 GMT 2025
|
PRIMARY | |||
|
218298-21-6
Created by
admin on Mon Mar 31 18:42:36 GMT 2025 , Edited by admin on Mon Mar 31 18:42:36 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|